Literature DB >> 9566349

Natural anti-immunoglobulin autoantibodies: irrelevant by-products or immunoregulatory molecules?

P Terness1, G Opelz.   

Abstract

Anti-immunoglobulin autoantibodies (anti-Ig auto-Abs), particularly IgM-anti-IgG (classical rheumatoid factor), have been studied mainly in the context of rheumatoid arthritis. In this article we focus on other members of the anti-Ig family, including the natural IgG-anti-F(ab')2 auto-Ab, and look for clinical and experimental findings supporting a role of these antibodies in the regulation of the immune response. We discuss the evidence for suppression of auto- and alloreactive B cells by IgG-anti-F(ab')2 auto-Ab and the role of this Ab in the pathogenesis of certain diseases, such as autoimmune hemolytic anemia. The structure of the antibody's antigen-binding site was clarified by isolating the VL and VH gene segments from the cDNA of B cells. Sequence analyses revealed germline gene identity of VL chains and 88% homology with the closest germline gene of VH chains. Finally, we discuss hypothetical models concerning the immunoregulatory role of natural anti-Ig auto-Abs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566349     DOI: 10.1159/000069457

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  8 in total

Review 1.  Intravenous immunoglobulin and recurrent pregnancy loss.

Authors:  Howard J A Carp; Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  Specificity of human anti-variable heavy (VH ) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1.

Authors:  J C Cordy; P J Morley; T J Wright; M A Birchler; A P Lewis; R Emmins; Y Z Chen; W M Powley; P J Bareille; R Wilson; J Tonkyn; A I Bayliffe; A L Lazaar
Journal:  Clin Exp Immunol       Date:  2015-09-11       Impact factor: 4.330

Review 3.  Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis.

Authors:  Leendert A Trouw; Theo Rispens; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

4.  Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1.

Authors:  M C Holland; J U Wurthner; P J Morley; M A Birchler; J Lambert; M Albayaty; A P Serone; R Wilson; Y Chen; R M Forrest; J C Cordy; D A Lipson; A I Bayliffe
Journal:  J Clin Immunol       Date:  2013-07-06       Impact factor: 8.317

5.  Differential requirements for induction of total immunoglobulin and physiological rheumatoid factor production by human peripheral blood B cells.

Authors:  W J Van Esch; C C Reparon-Schuijt; E W Levarht; C Van Kooten; F C Breedveld; C L Verweij
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

6.  Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

Authors:  Karen Thudium Mueller; Stephan A Grupp; Shannon L Maude; John E Levine; Michael A Pulsipher; Michael W Boyer; Keith J August; G Doug Myers; Constantine S Tam; Ulrich Jaeger; Stephen Ronan Foley; Peter Borchmann; Stephen J Schuster; Edmund K Waller; Rakesh Awasthi; Bernd Potthoff; Andy Warren; Edward R Waldron; Fraser McBlane; Andrea Chassot-Agostinho; Theodore W Laetsch
Journal:  Blood Adv       Date:  2021-12-14

7.  Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis.

Authors:  Keito Hoshitsuki; Sanjay Rathod; Manda J Ramsey; Lei Zhu; Larry W Moreland; Christian A Fernandez
Journal:  J Pharmacol Exp Ther       Date:  2020-10-02       Impact factor: 4.030

Review 8.  How immune complexes from certain IgG NAbs and any F(ab')₂ can mediate excessive complement activation.

Authors:  Hans U Lutz
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.